Comparative Pharmacology
Head-to-head clinical analysis: PREZCOBIX versus PREZCOBIX PED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PREZCOBIX versus PREZCOBIX PED.
PREZCOBIX vs PREZCOBIX PED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PREZCOBIX is a fixed-dose combination of darunavir, a HIV-1 protease inhibitor, and cobicistat, a CYP3A inhibitor. Darunavir selectively inhibits the cleavage of HIV-encoded Gag-Pol polyproteins in infected cells, preventing the formation of mature infectious virions. Cobicistat increases systemic exposure of darunavir by inhibiting CYP3A-mediated metabolism.
Darumavir is an HIV-1 protease inhibitor that inhibits the cleavage of HIV-1 Gag-Pol polyproteins, resulting in non-infectious immature viral particles. Cobicistat is a CYP3A inhibitor that boosts darunavir exposure without contributing to antiviral activity.
Darunavir 800 mg (as two 400 mg tablets) plus cobicistat 150 mg (as one 150 mg tablet) orally once daily with food.
PREZCOBIX PED is a pediatric formulation; adult dosing is not applicable. For adults, the equivalent product is PREZCOBIX (darunavir/cobicistat) fixed-dose combination: 800 mg/150 mg orally once daily with food.
None Documented
None Documented
Darunavir: terminal half-life of approximately 15 hours when coadministered with cobicistat, supporting once-daily dosing. Cobicistat: terminal half-life of approximately 3-4 hours, but its inhibitory effect on CYP3A4 persists for 24 hours.
Darunavir: ~15 hours (with cobicistat). Cobicistat: ~3-4 hours.
Darunavir: approximately 79.5% in feces (41% as unchanged drug) and 13.9% in urine (7.7% as unchanged drug). Cobicistat: 86% in feces and 8.2% in urine.
Darunavir: ~80% fecal (mostly as parent), ~14% renal (3% unchanged). Cobicistat: ~86% fecal, ~8% renal.
Category C
Category C
HIV Antiviral (Protease Inhibitor Combination)
HIV Antiviral (Protease Inhibitor Combination)